Press Releases April 30, 2026 04:05 PM

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics to Announce Q1 2026 Financial Results and Host Conference Call on May 7

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
AKBA

Akebia Therapeutics plans to release its first quarter 2026 financial results on May 7, 2026, prior to market open. The company will hold a conference call at 8:00 a.m. EDT the same day to discuss financials and recent business highlights. Akebia is a biopharmaceutical firm focused on kidney disease treatments, headquartered in Cambridge, Massachusetts.

Akebia Therapeutics to Report First Quarter 2026  Financial Results and Discuss Recent Business Highlights
AKBA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Akebia Therapeutics will report Q1 2026 financial results on May 7, 2026.
  • A conference call and webcast will be held to discuss results and business updates.
  • Akebia is dedicated to developing therapies for kidney disease patients.

Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT

CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026, prior to the open of financial markets.

Akebia will host a conference call on Thursday, May 7, 2026, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time. 

A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com


Risks

  • Financial results may not meet market expectations, impacting stock performance.
  • Biopharmaceutical sector regulatory and development challenges could affect outlook.
  • Market volatility in healthcare and biotech sectors may influence investor sentiment.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026